Blair R Leavitt, Mdcm

List of Publications by Year
in descending order

176 papers	20,512 citations	17440 63 h-index	11052 137 g-index
183 all docs	183 docs citations	183 times ranked	14528 citing authors

#	Article	IF	Citations
1	Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease. Science, 2001, 293, 493-498.	12.6	1,191
2	Huntington disease. Nature Reviews Disease Primers, 2015, 1, 15005.	30.5	1,031
3	Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nature Neuroscience, 2002, 5, 731-736.	14.8	925
4	Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews Neurology, 2014, 10, 204-216.	10.1	873
5	Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurology, The, 2009, 8, 791-801.	10.2	856
6	A YAC Mouse Model for Huntingtonâ€™s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration. Neuron, 1999, 23, 181-192.	8.1	789
7	Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Human Molecular Genetics, 2003, 12, 1555-1567.	2.9	713
8	Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurology, The, 2013, 12, 637-649.	10.2	704
9	Cleavage at the Caspase-6 Site Is Required for Neuronal Dysfunction and Degeneration Due to Mutant Huntingtin. Cell, 2006, 125, 1179-1191.	28.9	600
10	The current landscape of nucleic acid therapeutics. Nature Nanotechnology, 2021, 16, 630-643.	31.5	578
11	A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. Journal of Experimental Medicine, 2008, 205, 1869-1877.	8.5	559
12	Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease. Neuron, 2002, 33, 849-860.	8.1	553
13	Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurology, The, 2011, 10, 31-42.	10.2	530
14	Targeting Huntingtin Expression in Patients with Huntingtonâ€™s Disease. New England Journal of Medicine, 2019, 380, 2307-2316.	27.0	493
15	Caspase Cleavage of Mutant Huntingtin Precedes Neurodegeneration in Huntington's Disease. Journal of Neuroscience, 2002, 22, 7862-7872.	3.6	344
16	Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Human Molecular Genetics, 2007, 16, 1845-1861.	2.9	304
17	A one-hit model of cell death in inherited neuronal degenerations. Nature, 2000, 406, 195-199.	27.8	294
18	Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington's Disease. Journal of Neuroscience, 2005, 25, 4169-4180.	3.6	282

#	Article	IF	Citations
19	Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. Lancet Neurology, The, 2017, 16, 601-609.	10.2	272
20	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. Lancet Neurology, The, 2017, 16, 701-711.	10.2	248
21	Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11402-11407.	7.1	247
22	NMDA receptor function in mouse models of Huntington disease. Journal of Neuroscience Research, 2001, 66, 525-539.	2.9	246
23	Proteomic Profiling of Plasma in Huntington's Disease Reveals Neuroinflammatory Activation and Biomarker Candidates. Journal of Proteome Research, 2007, 6, 2833-2840.	3.7	212
24	Wild-Type Huntingtin Reduces the Cellular Toxicity of Mutant Huntingtin In Vivo. American Journal of Human Genetics, 2001, 68, 313-324.	6.2	210
25	Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntingtonâ€™s disease patients. Journal of Clinical Investigation, 2015, 125, 1979-1986.	8.2	209
26	Huntingtin Lowering Strategies for Disease Modification in Huntingtonâ€™s Disease. Neuron, 2019, 101, 801-819.	8.1	202
27	Age-Dependent Alterations of Corticostriatal Activity in the YAC128 Mouse Model of Huntington Disease. Journal of Neuroscience, 2009, 29, 2414-2427.	3.6	160
28	Diagnostic criteria for Huntington's disease based on natural history. Movement Disorders, 2014, 29, 1335-1341.	3.9	158
29	Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Human Molecular Genetics, 2005, 14, 3823-3835.	2.9	152
30	Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Human Molecular Genetics, 2005, 14, 1379-1392.	2.9	149
31	Wild-type huntingtin protects neurons from excitotoxicity. Journal of Neurochemistry, 2006, 96, 1121-1129.	3.9	145
32	Development of biomarkers for Huntington's disease. Lancet Neurology, The, 2011, 10, 573-590.	10.2	145
33	Synaptic dysfunction in progranulin-deficient mice. Neurobiology of Disease, 2012, 45, 711-722.	4.4	144
34	Progranulin in neurodegenerative disease. Trends in Neurosciences, 2014, 37, 388-398.	8.6	142
35	Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiology of Disease, 2006, 23, 190-197.	4.4	137
36	Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Human Molecular Genetics, 2002, 11, 1939-1951.	2.9	129

#	Article	IF	Citations
37	Differential Susceptibility to Excitotoxic Stress in YAC128 Mouse Models of Huntington Disease between Initiation and Progression of Disease. Journal of Neuroscience, 2009, 29, 2193-2204.	3.6	123
38	Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. EBioMedicine, 2015, 2, 1420-1429.	6.1	122
39	Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 687-694.	1.9	120
40	KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4676-E4685.	7.1	119
41	Progranulin expression in the developing and adult murine brain. Journal of Comparative Neurology, 2010, 518, 3931-3947.	1.6	115
42	Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. Human Brain Mapping, 2013, 34, 519-529.	3.6	113
43	A SNP in the HTT promoter alters NF-Î¹B binding and is a bidirectional genetic modifier of Huntington disease. Nature Neuroscience, 2015, 18, 807-816.	14.8	113
44	The Clinical and Genetic Features of Huntington Disease. Journal of Geriatric Psychiatry and Neurology, 2010, 23, 243-259.	2.3	112
45	Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiology of Disease, 2006, 21, 392-403.	4.4	108
46	Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiology of Disease, 2012, 45, 438-449.	4.4	105
47	A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes. EBioMedicine, 2019, 48, 568-580.	6.1	104
48	Body weight is modulated by levels of full-length Huntingtin. Human Molecular Genetics, 2006, 15, 1513-1523.	2.9	101
49	Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Human Molecular Genetics, 2010, 19, 1528-1538.	2.9	100
50	Depletion of wild-type huntingtin in mouse models of neurologic diseases. Journal of Neurochemistry, 2003, 87, 101-106.	3.9	97
51	Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiology of Disease, 2007, 26, 189-200.	4.4	97
52	Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology, 2017, 89, 2495-2502.	1.1	97
53	Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. Journal of Neurochemistry, 2005, 95, 210-220.	3.9	96
54	Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis. Human Molecular Genetics, 2010, 19, 1438-1452.	2.9	91

#	Article	IF	Citations
55	Testicular degeneration in Huntington disease. Neurobiology of Disease, 2007, 26, 512-520.	4.4	90
56	Iron dysregulation in Huntington's disease. Journal of Neurochemistry, 2014, 130, 328-350.	3.9	90
57	Huntingtin inhibits caspase-3 activation. EMBO Journal, 2006, 25, 5896-5906.	7.8	88
58	Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Scientific Reports, 2015, 5, 12166.	3.3	82
59	Phosphorylation of Huntingtin at Ser⁴²¹in YAC128 Neurons Is Associated with Protection of YAC128 Neurons from NMDA-Mediated Excitotoxicity and Is Modulated by PP1 and PP2A. Journal of Neuroscience, 2010, 30, 14318-14329.	3.6	81
60	Brain Regions Showing White Matter Loss inÂHuntingtonâ€™s Disease Are Enriched for Synaptic and Metabolic Genes. Biological Psychiatry, 2018, 83, 456-465.	1.3	79
61	CAG-encoded polyglutamine length polymorphism in the human genome. BMC Genomics, 2007, 8, 126.	2.8	78
62	Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiology of Disease, 2006, 21, 444-455.	4.4	77
63	Brain-specific Proteins Decline in the Cerebrospinal Fluid of Humans with Huntington Disease. Molecular and Cellular Proteomics, 2009, 8, 451-466.	3.8	76
64	YB-1 Bridges Neural Stem Cells and Brain Tumorâ€“Initiating Cells via Its Roles in Differentiation and Cell Growth. Cancer Research, 2011, 71, 5569-5578.	0.9	74
65	Movement Disorder Society Task Force Viewpoint: Huntington's Disease Diagnostic Categories. Movement Disorders Clinical Practice, 2019, 6, 541-546.	1.5	67
66	Reliability and Factor Structure of the Short Problem Behaviors Assessment for Huntingtonâ€™s Disease (PBA-s) in the TRACK-HD and REGISTRY studies. Journal of Neuropsychiatry and Clinical Neurosciences, 2015, 27, 59-64.	1.8	66
67	Neurofilament light protein in blood predicts regional atrophy in Huntington disease. Neurology, 2018, 90, e717-e723.	1.1	65
68	Operationalizing compensation over time in neurodegenerative disease. Brain, 2017, 140, 1158-1165.	7.6	62
69	Antisense oligonucleotides for neurodegeneration. Science, 2020, 367, 1428-1429.	12.6	62
70	Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Experimental Neurology, 2005, 196, 266-272.	4.1	60
71	8OHdG as a marker for Huntington disease progression. Neurobiology of Disease, 2012, 46, 625-634.	4.4	58
72	Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development. Alzheimer's and Dementia, 2013, 9, 176-188.	0.8	58

#	Article	IF	Citations
73	Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease. Journal of Neurochemistry, 2016, 139, 22-25.	3.9	58
74	Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components. Molecular Pharmaceutics, 2022, 19, 1669-1686.	4.6	58
75	The structural involvement of the cingulate cortex in premanifest and early Huntington's disease. Movement Disorders, 2011, 26, 1684-1690.	3.9	56
76	The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease. Neuropsychologia, 2015, 79, 138-146.	1.6	56
77	DNA methylation profiling in human Huntington's disease brain. Human Molecular Genetics, 2016, 25, 2013-2030.	2.9	56
78	Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease. Human Molecular Genetics, 2012, 21, 3097-3111.	2.9	55
79	Gender differences in expression of the human caspase-12 long variant determines susceptibility to Listeria monocytogenes infection. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9016-9020.	7.1	53
80	Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. Journal of Neurochemistry, 2005, 94, 1087-1101.	3.9	52
81	A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers. Movement Disorders, 2015, 30, 393-401.	3.9	50
82	Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models. Neurobiology of Disease, 2015, 73, 388-398.	4.4	50
83	The advantages of frontotemporal degeneration drug development (partÂ2Âof frontotemporal) Tj ETQq1 1 0.784314 rgBT /Overlock	0.8	48
84	Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay. Journal of Huntington's Disease, 2017, 6, 349-361.	1.9	48
85	Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease. BMC Neuroscience, 2006, 7, 80.	1.9	47
86	Tetrabenazine. Nature Reviews Drug Discovery, 2009, 8, 17-18.	46.4	47
87	Expression analysis of novel striatal-enriched genes in Huntington disease. Human Molecular Genetics, 2010, 19, 609-622.	2.9	45
88	Potential biomarkers to follow the progression and treatment response of Huntingtonâ€™s disease. Journal of Experimental Medicine, 2016, 213, 2655-2669.	8.5	45
89	Visuospatial Processing Deficits Linked to Posterior Brain Regions in Premanifest and Early Stage Huntingtonâ€™s Disease. Journal of the International Neuropsychological Society, 2016, 22, 595-608.	1.8	44
90	Association of CAG Repeats With Long-term Progression in Huntington Disease. JAMA Neurology, 2019, 76, 1375.	9.0	44

#	Article	IF	Citations
91	Quality of Life in Huntington's Disease: A Comparative Study Investigating the Impact for those with Pre-Manifest and Early Manifest Disease, and their Partners. Journal of Huntington's Disease, 2013, 2, 159-175.	1.9	43
92	Epidemiology of Huntington disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 144, 31-46.	1.8	43
93	Chapter 15 Juvenile amyotrophic lateral sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 82, 301-312.	1.8	42
94	p53 increases caspase-6 expression and activation in muscle tissue expressing mutant huntingtin. Human Molecular Genetics, 2014, 23, 717-729.	2.9	42
95	Correction of inter-scanner and within-subject variance in structural MRI based automated diagnosing. NeuroImage, 2014, 98, 405-415.	4.2	40
96	Huntingtin-Lowering Therapies for Huntington Disease. JAMA Neurology, 2020, 77, 764.	9.0	39
97	White matter predicts functional connectivity in premanifest Huntington's disease. Annals of Clinical and Translational Neurology, 2017, 4, 106-118.	3.7	38
98	Aquatherapy for Neurodegenerative Disorders. Journal of Huntington's Disease, 2014, 3, 5-11.	1.9	37
99	Topological length of white matter connections predicts their rate of atrophy in premanifest Huntingtonâ€™s disease. JCI Insight, 2017, 2, .	5.0	37
100	Spontaneous, solvent-free entrapment of siRNA within lipid nanoparticles. Nanoscale, 2020, 12, 23959-23966.	5.6	36
101	Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2015, 4, 109-118.	1.9	34
102	Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin. Neuroscience, 2016, 325, 74-88.	2.3	34
103	Testing a longitudinal compensation model in premanifest Huntingtonâ€™s disease. Brain, 2018, 141, 2156-2166.	7.6	33
104	Untargeted metabolomics and infrared ion spectroscopy identify biomarkers for pyridoxine-dependent epilepsy. Journal of Clinical Investigation, 2021, 131, .	8.2	33
105	Cerebrospinal fluid levels of orexinâ€A are not a clinically useful biomarker for Huntington disease. Clinical Genetics, 2006, 70, 78-79.	2.0	31
106	Recommendations for the Use of Automated Gray Matter Segmentation Tools: Evidence from Huntingtonâ€™s Disease. Frontiers in Neurology, 2017, 8, 519.	2.4	31
107	Corpus Callosal Atrophy in Premanifest and Early Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 517-526.	1.9	29
108	Mutant huntingtin expression in microglia is neither required nor sufficient to cause the Huntingtonâ€™s disease-like phenotype in BACHD mice. Human Molecular Genetics, 2019, 28, 1661-1670.	2.9	29

#	Article	IF	Citations
109	Proteolytic degradation of neuropeptide Y (<scp>NPY</scp>) from head to toe: Identification of novel <scp>NPY</scp>â€cleaving peptidases and potential drug interactions in <scp>CNS</scp> and Periphery. Journal of Neurochemistry, 2015, 135, 1019-1037.	3.9	28
110	Structural and functional brain network correlates of depressive symptoms in premanifest Huntington's disease. Human Brain Mapping, 2017, 38, 2819-2829.	3.6	28
111	PIAS1 modulates striatal transcription, DNA damage repair, and SUMOylation with relevance to Huntingtonâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	28
112	Ageâ€dependent alterations of the kynurenine pathway in the <scp>YAC</scp>128 mouse model of Huntington disease. Journal of Neurochemistry, 2013, 127, 852-867.	3.9	27
113	8OHdG is not a biomarker for Huntington disease state or progression. Neurology, 2013, 80, 1934-1941.	1.1	27
114	The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain. Experimental Neurology, 2013, 249, 144-148.	4.1	26
115	Direct intracerebral delivery of a miR-33 antisense oligonucelotide into mouse brain increases brain ABCA1 expression. Neuroscience Letters, 2015, 598, 66-72.	2.1	26
116	Selective depletion of microglial progranulin in mice is not sufficient to cause neuronal ceroid lipofuscinosis or neuroinflammation. Journal of Neuroinflammation, 2017, 14, 225.	7.2	26
117	Cross-species characterization of the ALS2 gene and analysis of its pattern of expression in development and adulthood. Neurobiology of Disease, 2005, 18, 243-257.	4.4	25
118	Progranulin promotes activation of microglia/macrophage after pilocarpine-induced status epilepticus. Brain Research, 2013, 1530, 54-65.	2.2	24
119	Core neuropathological abnormalities in progranulin-deficient mice are penetrant on multiple genetic backgrounds. Neuroscience, 2016, 315, 175-195.	2.3	24
120	Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease. NeuroImage: Clinical, 2018, 17, 312-324.	2.7	23
121	Re: Autopsyâ€proven Huntington's disease with 29 trinucleotide repeats. Movement Disorders, 2008, 23, 1794-1795.	3.9	20
122	Cocaineâ€and amphetamineâ€regulated transcript is increased in Huntington disease. Movement Disorders, 2007, 22, 1952-1954.	3.9	18
123	Natural variation in sensoryâ€motor white matter organization influences manifestations of Huntington's disease. Human Brain Mapping, 2016, 37, 4615-4628.	3.6	18
124	Development of an Î±-synuclein knockdown peptide and evaluation of its efficacy in Parkinsonâ€™s disease models. Communications Biology, 2021, 4, 232.	4.4	18
125	Intracerebroventricular Administration of AAV9-PHP.B SYN1-EmGFP Induces Widespread Transgene Expression in the Mouse and Monkey Central Nervous System. Human Gene Therapy, 2021, 32, 599-615.	2.7	18
126	Conditional loss of progranulin in neurons is not sufficient to cause neuronal ceroid lipofuscinosis-like neuropathology in mice. Neurobiology of Disease, 2017, 106, 14-22.	4.4	17

#	Article	IF	Citations
127	Altered Intracortical T1-Weighted/T2-Weighted Ratio Signal in Huntingtonâ€™s Disease. Frontiers in Neuroscience, 2018, 12, 805.	2.8	17
128	Satellog: a database for the identification and prioritization of satellite repeats in disease association studies. BMC Bioinformatics, 2005, 6, 145.	2.6	16
129	Visual Working Memory Impairment in Premanifest Gene-Carriers and Early Huntington's Disease. Journal of Huntington's Disease, 2012, 1, 97-106.	1.9	15
130	Postnatal muscle modification by myogenic factors modulates neuropathology and survival in an ALS mouse model. Nature Communications, 2013, 4, 2906.	12.8	15
131	Large-scale brain network abnormalities in Huntington's disease revealed by structural covariance. Human Brain Mapping, 2016, 37, 67-80.	3.6	15
132	A novel mouse model for pyridoxine-dependent epilepsy due to antiquitin deficiency. Human Molecular Genetics, 2020, 29, 3266-3284.	2.9	15
133	Transcriptional Regulation of the Huntingtin Gene. Journal of Huntington's Disease, 2018, 7, 289-296.	1.9	14
134	Executive impairment is associated with unawareness of neuropsychiatric symptoms in premanifest and early Huntingtonâ€™s disease.. Neuropsychology, 2018, 32, 958-965.	1.3	13
135	The Catalytic Function of Hormone-Sensitive Lipase is Essential for Fertility in Male Mice. Endocrinology, 2014, 155, 3047-3053.	2.8	12
136	Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis. JAMA Neurology, 2017, 74, 1352.	9.0	12
137	Composite <scp>UHDRS</scp> Correlates With Progression of Imaging Biomarkers in Huntington's Disease. Movement Disorders, 2021, 36, 1259-1264.	3.9	12
138	Design optimization for clinical trials in earlyâ€stage manifest Huntington's disease. Movement Disorders, 2017, 32, 1610-1619.	3.9	11
139	Neurobiology of Huntingtonâ€™s Disease. Current Topics in Behavioral Neurosciences, 2014, 22, 81-100.	1.7	10
140	Decreasing Levels of the cdk5 Activators, p25 and p35, Reduces Excitotoxicity in Striatal Neurons. Journal of Huntington's Disease, 2012, 1, 89-96.	1.9	9
141	Murine Models of Huntingtonâ€™s Disease for Evaluating Therapeutics. Methods in Molecular Biology, 2018, 1780, 179-207.	0.9	9
142	A systematic review and metaâ€analysis of clinical variables used in Huntington disease research. Movement Disorders, 2013, 28, 1987-1994.	3.9	8
143	Sensitivity to neurotoxic stress is not increased in progranulin-deficient mice. Neurobiology of Aging, 2013, 34, 2548-2550.	3.1	8
144	The Potential of Composite Cognitive Scores for Tracking Progression in Huntington's Disease. Journal of Huntington's Disease, 2014, 3, 197-207.	1.9	8

#	Article	IF	Citations
145	Detection of Motor Changes in Huntington's Disease Using Dynamic Causal Modeling. Frontiers in Human Neuroscience, 2015, 9, 634.	2.0	8
146	Human progranulin-expressing mice as a novel tool for the development of progranulin-modulating therapeutics. Neurobiology of Disease, 2021, 153, 105314.	4.4	8
147	Age-related mitochondrial alterations in brain and skeletal muscle of the YAC128 model of Huntington disease. Npj Aging and Mechanisms of Disease, 2021, 7, 26.	4.5	8
148	Safety and Feasibility of Research Lumbar Puncture in Huntingtonâ€™s Disease: The HDClarity Cohort and Bioresource. Journal of Huntington's Disease, 2022, 11, 59-69.	1.9	7
149	Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease. BMC Neurology, 2006, 6, 32.	1.8	6
150	Utility of Huntington's Disease Assessments by Disease Stage: Floor/Ceiling Effects. Frontiers in Neurology, 2021, 12, 595679.	2.4	6
151	Longitudinal expression changes are weak correlates of disease progression in Huntingtonâ€™s disease. Brain Communications, 2020, 2, fcaa172.	3.3	6
152	Huntington Disease. , 2008, , 207-266.		5
153	F23â€...Validity, reliability, ability to detect change and meaningful within-patient change of the CUHDRS. , 2018, , .		5
154	Longitudinal Structural <scp>MRI</scp> in Neurologically Healthy Adults. Journal of Magnetic Resonance Imaging, 2020, 52, 1385-1399.	3.4	5
155	Is tetrabenazine safe and effective for suppressing chorea in Huntington's disease?. Nature Clinical Practice Neurology, 2006, 2, 536-537.	2.5	4
156	Huntington's disease: A field on the move. Movement Disorders, 2014, 29, 1333-1334.	3.9	4
157	Clinical utility gene card for: Huntingtonâ€™s disease. European Journal of Human Genetics, 2014, 22, 713-713.	2.8	4
158	Treatment of Huntington Disease and Comorbid Trichotillomania With Aripiprazole. Journal of Neuropsychiatry and Clinical Neurosciences, 2015, 27, e211-e212.	1.8	4
159	p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntingtonâ€™s disease. Neuroscience, 2017, 352, 79-87.	2.3	3
160	Computational Analysis of Transcriptional Regulation Sites at the HTT Gene Locus. Journal of Huntington's Disease, 2018, 7, 223-237.	1.9	2
161	Murine Models of HD. , 2015, , 533-546.		1
162	Editorial on Clinical Trialâ€™s Corner. Journal of Huntington's Disease, 2018, 7, 87-87.	1.9	1

#	Article	IF	Citations
163	Isolating cells from adult murine brain for validation of cell-type specific cre-mediated deletion. Journal of Neuroscience Methods, 2019, 328, 108422.	2.5	1
164	Cystamine and ethyl-eicosapentaenoic acid treatment fail to prevent malonate-induced striatal toxicity in mice. Neurobiology of Aging, 2011, 32, 2326.e1-2326.e4.	3.1	0
165	Journal of Huntington's Disease. Journal of Huntington's Disease, 2012, 1, 1-1.	1.9	0
166	Editorial. Journal of Huntington's Disease, 2013, 2, 1-1.	1.9	0
167	D21â€...Longitudinal compensation in the cognitive network in huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A42.1-A42.	1.9	0
168	D22â€...Compensation in preclinical huntingtonâ€™s disease: evidence from the track-on HD study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A42.2-A42.	1.9	0
169	Introducing the â€œClinical Trials Cornerâ€. Journal of Huntington's Disease, 2017, 6, 167-167.	1.9	0
170	D10â€...Neurofilament light protein in blood predicts regional atrophy in huntingtonâ€™s disease. , 2018, , .		0
171	E11â€...Compensation in huntingtonâ€™s disease. , 2018, , .		0
172	J03â€...Partial lowering of total huntingtin levels to treat adults with huntingtonâ€™s disease (hd): potential benefits and theoretical risks from human studies and animal models. , 2018, , .		0
173	C01â€...Glutamine codon usage and somatic mosaicism of the HTT cag repeat are modifiers of huntington disease severity. , 2018, , .		0
174	Murine models of Huntington disease. Future Neurology, 2009, 4, 617-638.	0.5	0
175	D08â€...Neurofilament light protein in blood as a potential biomarker of neurodegeneration in hungtingtonâ€™s disease: a retrospective cohort analysis. , 2018, , .		0
176	234â€... Using functional status to aid interpretation of cUHDRS scores in patients with Huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A81.1-A81.	1.9	0